Ebf1 in malignant transformation, we investigated the impact of reduced functional
Ebf1 dosage on mouse B-cell progenitors. Gene expression analysis suggested that Ebf1 was involved in the regulation of genes important for DNA repair as well as cell survival. Investigation of the DNA damage in steady state as well as after induction of DNA damage by UV light, confirmed that pro-B cells lacking one functional allele of Ebf1 display signs of increased DNA damage. This correlated to reduced expression of DNA repair genes including Rad51 and chromatin immunoprecipitation data suggested that Rad51 is a direct target for Ebf1. Although reduced dosage of Ebf1 did not significantly increase tumor formation in mice, a dramatic increase in the frequency of pro-B cell leukemia was observed in mice with combined heterozygous mutations in the Ebf1 and Pax5 genes revealing a synergistic effect of combined dose reduction of these proteins. Our data suggest that Ebf1 controls DNA repair in a dose dependent manner providing a possible explanation to the frequent involvement of EBF1 gene loss in human leukemia.
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Introduction:
One of the central proteins in B-lymphocyte development is the transcription factor Early B-cell factor 1 (Ebf1) 1 Ebf1 levels are also of relevance in leukemia because mutations resulting in reduced functional EBF1 dose 9,10 and increased expression of post-transcriptional inhibitors of EBF1, ZNF521 11 or ZNF423 12 is found in B-cell acute lymphoblastic leukemia (B-ALL) 13, 14 . A direct role for Ebf1 dose in malignant transformation was supported by the findings that combined expression of constitutively active Stat5 (caStat5) and heterozygous loss of either Ebf1 or Pax5 results in B-cell leukemia in mice 15 .
Heterozygote deletion of PAX5 is a rather common genetic alteration in human B-ALL 9,10 and a genetic polymorphism causing reduced functional PAX5 activity has been found in families with a high incidence of leukemia 16 . The finding that the developmental block observed in Pax5-deficient leukemia cells can be reversed upon restoration of Pax5 expression suggests that the reduction in Pax5 function results in a reversible disruption of differentiation 17 . A similar mechanism of action has been proposed for Ebf1, however, reduced amounts of Ebf1 in normal cells appear to result in reduced proliferation and expansion of B-cell progenitors 4, 6, 18, 19 indicating that the involvement of EBF1 in malignant transformation is more complex.
In order to increase our understanding of the functions of Ebf1 in malignant transformation, we identified dose dependent processes regulated by Ebf1 in early B- 16 , we investigated the functional collaboration between Ebf1 and Pax5 in leukemogenesis revealing a strong functional synergy on the development of leukemia. Together, our data suggest that reduced levels of Ebf1 may contribute to malignant transformation by a combination of impaired DNA repair and increased cell survival rather than simply by a differentiation block.
Results.

Reduced amounts of Ebf1 increase DNA damage in pro-B cells.
Ebf1 is a crucial regulator of cell differentiation, however, conditional deletion of the Ebf1 gene in B-cell progenitors reveals additional roles for this transcription factor in proliferation and cell survival 4, 18, 19 . peripheral blood (51-89%) and spleens (37-92%) ( Figure S3 , Table SIII) . Similar results were obtained 3 weeks after transplantation of lymphnode cells to nonirradiated mice (Table II, Table SIII ). These data support the idea that the pro-B cell expansion observed in several of the Pax5 +/-Ebf1 +/-mice is caused by malignant transformation resulting in progenitor B cell leukemia.
Ectopic expression of Bcl2 in combination with heterozygous deletion of Pax5 results
in pro-B cell expansion but does not cause leukemia.
Knowing that combined reductions of Pax5 and Ebf1 result in malignant disease, we wanted to assess the potential contribution of increased Bcl2 expression per se in the transformation process. This could be of potential interest because it has been reported that homozygous deletion of Pax5 genes in combination with transgenic expression of Bcl2 result in B-cell leukemia 24 . To this end we crossed Pax5 +/-mice to animals expressing human BCL2 under the regulatory elements of the vav-1 gene 25 .
Analysis (Table III) . Two of the tumors presented with a higher degree of unique changes and while tumor LN327 carried a major part of the alterations on chromosome 11, the alterations in LN317 were more interspersed in the genome. In conclusion, the tumor populations arising after combined heterozygous loss of Ebf1 and Pax5 similarly represent early B-cell progenitors, but display a substantial molecular heterogeneity consistent with the idea that tumor formation involves secondary events as could be anticipated by a defect in DNA repair. (Table III) 
Experimental procedures
Animal models.
Pax5
+/-31 , Ebf1 +/-3 or vav-BCL2 25 were all on C57BL/6 (CD45.2) background.
Adoptive transfers were performed by tail vein injection of 2 million live lymphnode cells into sublethally irradiated (4.5 Gy) or non conditioned CD45.1 mice. Animal procedures were performed with consent from the local ethics committee at Linköping University (Linköping, Sweden).
Western blot.
Western blot were made using extracts from cultured primary pro B cells from bone 
Comet assay.
The comet assay was performed using the reagents from OxiSelect Comet assay kit (Cell Biolabs, CA, USA) according to manufactures instructions (See SM for details).
Comets were viewed using Zeiss upright confocal microscope (ZEISS, Germany) in FITC channel using 20X objective.
FACS staining and sorting of hematopoietic cells.
Cell sorting of and analysis of primary cells was performed as in 6 (For details see SM). Cellular composition in the primary tumors were analyzed using frozen single cell suspensions from lymph node, BM and spleen while the composition in the organs of transplanted mice was performed on freshly isolated tissues and blood.
Gene expression analysis with Quantitative RT-PCR and Affymetrix.
Q-RT-PCR and Affymetrix based global gene expression analysis of sorted cells was performed as previously described 33 (See SM for details). Data are deposited at GEO, GSE67415.
VDJ-recombination and Exome sequencing analysis.
Live cells were sorted and DNA was extracted and subjected to PCR based VDJ analysis 34 . For exome sequencing the DNA was fragmented and enriched for coding regions followed by sequencing to gain an avargae cover of 100X and the obtained data was analysed using the Mutech software 26 (See SM for details).
Statistical analysis.
The statistical analysis is described in the corresponding figure legends.
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